Abstract
The purpose of the study was to determine, in addition to well-known prognostic factors, histological grade, stage, tumour size and multiplicity, the correlation of BTA stat Test on disease free interval (DFI) on primary superficial bladder cancer. A total of 116 patients with newly diagnosed bladder cancer were evaluated in a prospective multicentre study. A voided urine sample was obtained prior to TURB and split for culture, cytology and BTA stat testing. Follow-up data for the patients were collected until the first recurrence or the last visit and the DFI was analysed by Kaplan–Meier method and Cox analysis. Ninety-seven of the 116 (83.6%) patients were eligible for analysis. The BTA stat Test was positive in 73 (75.3%) patients, whereas cytology detected 20 (20.6%) cases. The DFI was found to be shorter among patients with a positive BTA stat Test, and also among those with intermediate or high-grade tumours. The BTA stat Test result divided patients with grade 2 tumours into two prognostic groups, in that those testing positive had 68.6% risk of recurrence during the first year compared to 42.9% risk of those with a negative test result (P = 0.041). Although the effect of tumour size on DFI was notable, the difference did not reach statistical significance (P = 0.064). Number of tumours was not related to DFI, nor was the difference between different stage of tumour of significance. BTA stat Test is not only sensitive in detection of primary bladder cancer, but also might have some independent prognostic significance. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Corey MJ, Kinders RJ, Brown L, Rowley H and Vessela R (1998) Factor H related proteins are upregulated in bladder cancer. Proc Am Assn Cancer Res 39: 263 (abstr)
Fitzpatrick JM, West AB and Butler MR (1986) Superficial bladder tumours (stage pTa, grades 1 and 2): The importance of recurrence pattern following initial resection. J Urol 135: 920–922
Heney NM, Nocks BN, Daly JJ, Prout GR Jr, Newall JB, Griffin BB, Perrone TL and Szyfelbein WA (1982) Ta and T1 bladder cancer: Location, recurrence and progression. Br J Urol 54: 152–157
Heney NM, Ahmed S, Flanagan MJ, Frable W, Corder MP, Hafermann M and Hawkins IR (1983) Superficial bladder cancer: progression and recurrence. J Urol 130: 1083–1086
Kiemeney LALM, Witjes JA, Heijbroek RP, Verbeek ALM and Debruyne FMJ (1993) Predictability of recurrent and progressive disease in individual patients with primary superficial bladder cancer. J Urol 150: 60–64
Kinders R, Root R, Jones J, Bruce C and Hass M (1997a) Complement factor H-related proteins are expressed in bladder cancer. Proceedings of the Eighty–Eighth Annual Meeting of American Association for Cancer Research, San Diego, CA USA 38: 29, Abstract No. 189
Kinders R, Jones J, Root R, Murchison H, Bruce C, Williams L and Hass M (1997b) Human bladder Tumour antigen is a member of the RCA (regulators of complement activation) gene family. J Urol 157: 28, Abstract no. 110
Kinders R, Jones T, Root R, Bruce C, Murchison H, Corey M, Williams L, Enfield D and Hass GM (1998) Complement Factor H or a related protein is a marker for transitional cell cancer of the bladder. Clinical Cancer Research 4: 2511–2520
Koch M, Hill GB and McPhee S (1986) Factors affecting recurrence rates in superficial bladder cancer. J Natl Cancer Inst 76: 1025–1029
Kurth KH, Denis L, Bouffioux CH, Sylvester R, Debruyne FM, Pavone–Macaluso M and Oosterlink W (1995) Factors effecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A: 1840–1846
Lutzeyer W, Rübben H and Dahm H (1982) Prognostic parameters in superficial bladder cancer: and analysis of 315 cases. J Urol 127: 250–252
Malmström P–U, Busch C and Norlén BJ (1987) Recurrence, progression and survival in bladder cancer. Scand J Urol Nephrol 21: 185–195
Morris SB, Gordon EM, Shearer RJ and Woodhouse CRJ (1995) Superficial bladder cancer: for how long should a tumour-free patient have check cystoscopies?. Br J Urol 75: 193–196
Mostofi FK, Sobin LH and Torloni H (1973) Histological typing of urinary bladder tumours. World Health Organization: Geneva
Parmar MKB, Freedman LS, Hargreave TB and Tolley DA (1989) Prognostic factors for recurrence and follow-up policies in the treatment of superficial bladder cancer: report from the British Medical Research Council Subgroup on Superficial Bladder Cancer. J Urol 142: 284–288
Parmar MKB and Machin D (1995) Survival analysis. A practical approach John Wiley Chichester
Pode D, Shapiro A, Wald M, Nativ O, Laufer M and Kaver I (1999) Noninvasive detection of bladder cancer with the BTA stat test. J Urol 161: 443–446
Raitanen M-P and Tammela TLJ (1995) Impact of tumour grade, stage, number and size, smoking and sex on the recurrence rate and disease-free interval in patients with transitional cell carcinoma of the bladder. Ann Chir et Gyn 84: 37–41
Raitanen M-P, Marttila T, Kaasinen E, Rintala E, Aine R and Tammela TLJ (2000) Sensitivity of human complement factor H related protein (the BTA stat Test) test and voided urine cytology in the diagnosis of bladder cancer. J Urol 163: 1689–1692
Sarosdy M, Hudson M, Ellis WJ, Soloway MS, deVere White R, Sheinfeld J, Jarowenko MV, Schelhammer PF, Schervish EW, Patel JV, Chodak GW, Lamm DL, Johnson RD, Henderson M, Adams G, Blumenstein BA, Thoelke KR, Pfalzgraf RD, Murchison HA and Brunelle SL (1997) Improved detection of recurrent bladder cancer using the Bard BTA stat Test. Urology 50: 349–353
SPSS (1999) Advanced Models 9.0. SPSS Inc: Chigaco
Thompson RA Jr, Campbell EW Jr and Kramer HC (1993) Late invasive recurrence despite long-term surveillance for superficial bladder cancer. J Urol 149: 1010–1011
Union Internationale Contre le Cancer (1978) TNM Classification of Malignant Tumours. International Union Against Cancer: Geneva
Author information
Authors and Affiliations
Consortia
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Raitanen, MP., Kaasinen, E., Rintala, E. et al. Prognostic utility of human complement factor H related protein test (the BTA stat ®Test). Br J Cancer 85, 552–556 (2001). https://doi.org/10.1054/bjoc.2001.1938
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2001.1938
Keywords
This article is cited by
-
Improved survival prognostication of node-positive malignant melanoma patients utilizing shotgun proteomics guided by histopathological characterization and genomic data
Scientific Reports (2019)
-
The role of BTA stat Test in follow-up of patients with bladder cancer: results from FinnBladder studies
World Journal of Urology (2008)